DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice

Brain Research

Volumn 1048, Issue 1-2, 2005, Pages 177-184

  Lautar, Susan L ^a   Rojas, Camilo ^a   Slusher, Barbara S ^a   Wozniak, Krystyna M ^a   Wu, Ying ^a   Thomas, Ajit G ^a   Waldon, Daniel ^a   Li, William ^a   Ferraris, Dana ^a   Belyakov, Sergei ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Amphetamine induced hyperactivity; CD26; DPP IV; Enzyme inhibition; Mescaline induced scratching; NPY; Peptide; Psychosis; Schizophrenia

Indexed keywords

1 (2 AMINO 3 METHYLBUTYRYL)AZETIDINE 2 CARBONITRILE; 1 (2 DIMETHYLAMINO 3 METHYLBUTYRYL)AZETIDINE 2 CARBONITRILE; AMPA RECEPTOR; AMPHETAMINE; AZETIDINE DERIVATIVE; CANNABINOID 1 RECEPTOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DRUG ANALOG; GLUTAMATE RECEPTOR; GLYCINE RECEPTOR; KAINIC ACID RECEPTOR; MESCALINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HYPERACTIVITY; IC 50; MALE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA; SCRATCHING; STATISTICAL SIGNIFICANCE;

AMPHETAMINE; ANIMALS; AZA COMPOUNDS; AZETIDINES; BEHAVIOR, ANIMAL; DIABETES MELLITUS; DIPEPTIDYL PEPTIDASES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALOPERIDOL; HYPERKINESIS; HYPERSENSITIVITY; INHIBITORY CONCENTRATION 50; MALE; MESCALINE; MICE; MOTOR ACTIVITY; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; TIME FACTORS;

EID: 20444395442     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.04.069     Document Type: Article

References (27)

1. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J.W. Eriksson, S. Dickinson, and D. Holmes Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875
2. H.C. Akunne, S.Z. Whetzel, J.N. Wiley, A.E. Corbin, F.W. Ninteman, H. Tecle, Y. Pei, T.A. Pugsley, and T.G. Heffner The pharmacology of the novel and selective sigma ligand, PD 144418 Neuropharmacology 36 1997 51 62
3. S. Belyakov, G. Hamilton, D.S. Hurst, V.J. Kalish, W. Li, E. Wang, D. Wilkinson, Y. Wu, X. Xu, Patent WO 03/057666 (2003).
4. D.L. Blackmon, A.J. Watson, and M.H. Montrose Assay of apical membrane enzymes based on fluorogenic substrates Anal. Biochem. 200 1992 352 358
5. J.R. Bossier, and P. Simon Action de la cafeine sur a la motile spontanee de la souris Arch. Int. Pharmacodyn. 158 1965 212 221
6. L. Cook, S.W. Tam, and K.W. Rohrbach DuP 734 [1-(cyclopropylmethyl)-4- (2′(4-fluorophenyl)-2′-oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects J. Pharmacol. Exp. Ther. 263 1992 1159 1166
7. B. Costall, S.K. Lim, and R.J. Naylor Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice Eur. J. Pharmacol. 73 1981 175 188
8. B. Costall, A.M. Domeney, M.E. Kelly, R.J. Naylor, and D.M. Tomkins Actions of ORG 5222 as a novel psychotropic agent Pharmacol. Biochem. Behav. 35 1990 607 615
9. J.F. Deegan, and L. Cook A study of the antimescaline property of a series of CNS active agents in mice J. Pharmacol. Exp. Ther. 122 1958 17A
10. D.J. Drucker, Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. Cooper, and P.L. Brubaker Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV Nat. Biotechnol. 15 1997 673 677
11. P. Haninec, and M. Grim Localization of dipeptidylpeptidase IV and alkaline phosphatase in developing spinal cord meninges and peripheral nerve coverings of the rat Int. J. Dev. Neurosci. 8 2 1990 175 185
12. B. Hartmann, M.B. Harr, P.B. Jeppesen, M. Wojdemann, C.F. Deacon, P.B. Mortensen, and J.J. Holst In vivo and in vitro degradation of glucagon-like peptide-2 in humans J. Clin. Endocrinol. Metab. 85 2000 2884 2888
13. T. Karl, T. Hoffmann, R. Pabst, and S. von Horsten Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity Pharmacol. Biochem. Behav. 75 2003 869 879
14. A. Kask, J. Harro, S. von Horsten, J.P. Redrobe, Y. Dumont, and R. Quirion The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y Neurosci. Biobehav. Rev. 26 2002 259 283
15. J. Kuromitsu, A. Yokoi, T. Kawai, T. Nagasu, T. Aizawa, S. Haga, and K. Ikeda Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder Gene Expr. Patterns 1 2001 17 21
16. M. Maes, I. De Meester, S. Scharpe, R. Desnyder, R. Ranjan, and H.Y. Meltzer Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs Acta Psychiatr. Scand. 93 1996 1 8
17. M. Maes, L. Capuron, A. Ravaud, N. Gualde, E. Bosmans, B. Egyed, R. Dantzer, and P.J. Neveu Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy Neuropsychopharmacology 24 2001 130 140
18. F. Mauvais-Jarvis, F. Andreelli, H. Hanaire-Broutin, B. Charbonnel, and J. Girard Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights Diabetes Metab. 27 2001 415 423
19. C. Nilsson, A. Westman, K. Blennow, and R. Ekman Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry Peptides 19 1998 1137 1146
20. D. Rodi, M. Mazzuferi, G. Bregola, Y. Dumont, A. Fournier, R. Quirion, and M. Simonato Changes in NPY-mediated modulation of hippocampal [3H]D-aspartate outflow in the kindling model of epilepsy Synapse 49 2003 116 124
21. C.S. Sakurada, S. Hayashi, T. Katsuyama, S. Tan-No, and K.T. Sakuraada Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptydal peptidase IV: an in vitro and in vivo study Biochem. Pharmacol. 66 2003 653 661
22. A. Sedo, and R.P. Revoltella Detection of dipeptidyl peptidase IV in glioma C6 and neuroblastoma SK-N-SH cell lines Biochem. Cell. Biol. 73 1995 113 115
23. Y. Shirayama, H. Mitsushio, K. Takahashi, and T. Nishikawa Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions Synapse 35 2000 292 299
24. R.D. Soignier, A.L. Vaccarino, A.M. Brennan, A.J. Kastin, and J.E. Zadina Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice Life Sci. 67 2000 907 912
25. C. Tomboly, A. Peter, and G. Toth In vitro quantitative study of the degradation of endomorphins Peptides 23 9 2002 1573 1580
26. C. Tomboly, A. Peter, and G. Toth In vitro quantitative study of the degradation of endomorphins Peptides 23 2002 1573 1580
27. V.E. Woods, and A. Ettenberg Increased amphetamine-induced locomotion during inactivation of the basolateral amygdala Behav. Brain Res. 149 2004 33 39